Carlos E Prada1, Robert B Hufnagel2, Trent R Hummel3, Anne M Lovell2, Robert J Hopkin2, Howard M Saal2, Elizabeth K Schorry2. 1. Division of Human Genetics, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH; University of Cincinnati College of Medicine, Cincinnati, OH; Center for Genomic Medicine and Metabolism, Fundación Cardiovascular de Colombia, Floridablanca, Colombia. Electronic address: carlos.prada@cchmc.org. 2. Division of Human Genetics, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH; University of Cincinnati College of Medicine, Cincinnati, OH. 3. University of Cincinnati College of Medicine, Cincinnati, OH; Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
Abstract
OBJECTIVE: To evaluate the utility of screening brain/orbital magnetic resonance imaging (MRI) in a large population of children with neurofibromatosis type 1 (NF1) over a 20-year period. STUDY DESIGN: A retrospective analysis of clinical and imaging data from children with NF1 seen at a single center between 1990 and 2010 was performed. RESULTS: During the 20-year study period, 826 individuals with NF1 (402 females, 424 males) ages 1-9 years were screened for optic pathway gliomas (OPGs) using brain/orbital MRI; 18% were identified with OPGs with a median age at detection of 3 years. Fifteen percent of patients with OPGs had radiologic or clinical progression requiring therapy. Children with chiasmatic and postchiasmatic tumors were more likely to require therapy compared with patients with prechiasmatic OPGs (P < .0001). Patients with visual deficits at the time of diagnosis were more likely to experience visual decline despite therapy when compared with patients treated based on radiologic progression (P < .012). CONCLUSIONS: Our findings confirm that chiasmatic and postchiasmatic OPG in children with NF1 have the highest risk for progression and vision loss. Early identification of OPG by screening MRI prior to the development of vision loss may lead to improved visual outcomes. Children with negative brain and orbital MRI screening at age 15 months or later did not develop symptomatic OPGs.
OBJECTIVE: To evaluate the utility of screening brain/orbital magnetic resonance imaging (MRI) in a large population of children with neurofibromatosis type 1 (NF1) over a 20-year period. STUDY DESIGN: A retrospective analysis of clinical and imaging data from children with NF1 seen at a single center between 1990 and 2010 was performed. RESULTS: During the 20-year study period, 826 individuals with NF1 (402 females, 424 males) ages 1-9 years were screened for optic pathway gliomas (OPGs) using brain/orbital MRI; 18% were identified with OPGs with a median age at detection of 3 years. Fifteen percent of patients with OPGs had radiologic or clinical progression requiring therapy. Children with chiasmatic and postchiasmatic tumors were more likely to require therapy compared with patients with prechiasmatic OPGs (P < .0001). Patients with visual deficits at the time of diagnosis were more likely to experience visual decline despite therapy when compared with patients treated based on radiologic progression (P < .012). CONCLUSIONS: Our findings confirm that chiasmatic and postchiasmatic OPG in children with NF1 have the highest risk for progression and vision loss. Early identification of OPG by screening MRI prior to the development of vision loss may lead to improved visual outcomes. Children with negative brain and orbital MRI screening at age 15 months or later did not develop symptomatic OPGs.
Authors: Saba Sharif; Rosalie Ferner; Jillian M Birch; James E Gillespie; H Rao Gattamaneni; Michael E Baser; D Gareth R Evans Journal: J Clin Oncol Date: 2006-06-01 Impact factor: 44.544
Authors: Michael J Fisher; Michael Loguidice; David H Gutmann; Robert Listernick; Rosalie E Ferner; Nicole J Ullrich; Roger J Packer; Uri Tabori; Robert O Hoffman; Simone L Ardern-Holmes; Trent R Hummel; Darren R Hargrave; Eric Bouffet; Joel Charrow; Larissa T Bilaniuk; Laura J Balcer; Grant T Liu Journal: Neuro Oncol Date: 2012-04-03 Impact factor: 12.300
Authors: Kelly A Diggs-Andrews; Jacquelyn A Brown; Scott M Gianino; Joshua B Rubin; David F Wozniak; David H Gutmann Journal: Ann Neurol Date: 2014-02-06 Impact factor: 10.422
Authors: Peter M K de Blank; Michael J Fisher; Grant T Liu; David H Gutmann; Robert Listernick; Rosalie E Ferner; Robert A Avery Journal: J Neuroophthalmol Date: 2017-09 Impact factor: 3.042
Authors: Robert A Avery; Awais Mansoor; Rabia Idrees; Carmelina Trimboli-Heidler; Hiroshi Ishikawa; Roger J Packer; Marius George Linguraru Journal: Neurology Date: 2016-11-04 Impact factor: 9.910
Authors: Ezekiel Maloney; A Luana Stanescu; Francisco A Perez; Ramesh S Iyer; Randolph K Otto; Sarah Leary; Lotte Steuten; Amanda I Phipps; Dennis W W Shaw Journal: Pediatr Radiol Date: 2018-05-22
Authors: Elisa R Torres; Tyler A Tumey; Douglas C Dean; Wondwosen Kassahun-Yimer; Eloise D Lopez-Lambert; Mary E Hitchcock Journal: Int J Nurs Stud Date: 2020-02-22 Impact factor: 5.837
Authors: Alfred I Neugut; Paul Sackstein; Grace C Hillyer; Judith S Jacobson; Jeffrey Bruce; Andrew B Lassman; Philip A Stieg Journal: Oncologist Date: 2018-10-10